Clinical Trial Update: A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

This document reports a Phase 3 clinical trial evaluating two subcutaneous doses of amlitelimab versus treatment withdrawal in participants aged 12 and older wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Amlitelimab (amlitelimab)

Snippet

Sponsor: Sanofi | Conditions: Dermatitis Atopic | Phase 3 | Status: ACTIVE_NOT_RECRUITING